Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGFβ pathway

Cancer Prevention Research

Volumn 7, Issue 10, 2014, Pages 1045-1055

  Bokhari, Amber A ^a   Lee, Laura R ^a   Raboteau, Dewayne ^a   Hamilton, Chad A ^b   Maxwell, George L ^c   Rodriguez, Gustavo C ^d   Syed, Viqar ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Division of Gynecologic Oncology Gynecologic Cancer Translational Research Center of Excellence   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN; VIMENTIN; CADHERIN; CDH1 PROTEIN, HUMAN; CULTURE MEDIUM; LIGAND; SMAD4 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; CULTURE MEDIUM; ENDOMETRIAL NEOPLASMS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE MICROSCOPY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CADHERINS; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA; CULTURE MEDIA, CONDITIONED; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LIGANDS; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; PROGESTERONE; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84907551767     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0054     Document Type: Article

References (49)

1. Smith AL, Robin TP, Ford HL. Molecular pathways: Targeting the TGF-b pathway for cancer therapy. Clin Cancer Res 2012;18:4514-21.
2. Drabsch Y, ten Dijke P. TGF-b signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012;31:553-68.
3. Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-b therapies in cancer and fibrosis. Growth Factors 2011;29:140-52.
4. Massagué J. TGFb signaling in context. Nat Rev Mol Cell Biol 2012;13:616-30.
5. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, et al. Secreted transforming growth factor beta2 activates NF kappa B, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 2004;101:7112-17.
6. Van Themsche C, Mathieu I, Parent S, Asselin E. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of Xlinked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem 2007;282: 4794-802.
7. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
8. Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, et al. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 1994;54:2347-58.
9. Zakrzewski PK, Mokrosinski J, Cygankiewicz AI, Semczuk A, Rechberger T, Skomra D, et al. Dysregulation of betaglycan expression in primary human endometrial carcinomas. Cancer Invest 2011;29: 137-44.
10. Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M, et al. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Gynecol Oncol 2005;98:427-33.
11. Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, Dupont NC, Clark K, et al. Expression and clinical significance of the transforming growth factor-b signalling pathway in endometrial cancer. Histopathology 2011;59:63-72.
12. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-b receptor in human cancer. Cell Signal 2010;22:1163-74.
13. Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, et al. Type III TGF-b receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia 2011;13:758-70.
14. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
15. Kang Y, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004;118:277-79.
16. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
17. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010;21:49-59.
18. Katsuno Y, Lamouille S, Derynck R. TGF-b signaling and epithelialmesenchymal transition in cancer progression. Curr Opin Oncol 2013;25:76-84.
19. Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: Therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009;13:227-34.
20. Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009;277:114-20.
21. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010;9:122.
22. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Cancer 1991;49:870-4.
23. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535-40.
24. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997;79:320-7.
25. Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 2006;21:1070-5.
26. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60.
27. Rodriguez GC, Rimel BJ, Watkin W, Turbov J, Barry C, Maxwell GL, et al. Progestin treatment induces apoptosis and modulates TGF-b in the uterine endometrium. Cancer Epidemiol Biomarkers Prev 2008; 17:578-84.
28. Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso- Nocelo M, Bouso M, et al. High-risk endometrial carcinoma profiling identifies TGF-b1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 2011;10:1357-66.
29. Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol 2011;27:830-6.
30. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011;23:951-62.
31. Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982;247:475-7.
32. Vessey M, Painter R, Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9.
33. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
34. Vereide AB, Kaino T, Sager G, Ørbo A. Scottish gynaecological clinical trials group. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2005;97:740-50.
35. Orbo A, Rise CE, Mutter GL. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 2006;66:5613-7.
36. Akhrust RJ, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11:S44-S51.
37. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003; 100:8621-3.
38. Perlino E, Loverro G, Maiorano E, Giannini T, Cazzolla A, Napoli A, et al. Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma. Br J Cancer 1998;77: 1260-6.
39. Yabushita H, Narumiya H, Hiratake K, Yamada H, Shimazu M, Sawaguchi K, et al. The association of transforming growth factor- beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. J Obstet Gynaecol Res 2000;26:163-70.
40. Lee LR, Teng PN, Nguyen H, Hood BL, Kavandi L, Wang G, et al. Progesterone enhances calcitriol antitumor activity by up regulating vitamin Dreceptor expression and promoting apoptosis in endometrial cancer cells. Cancer Prev Res (Phila) 2013;6:731-43.
41. Tan AR, Alexe G, Reiss M. Transforming growth factor-b signaling emerging stem cell target in metastatic breast cancer. Breast Cancer Res Treat 2009;115:1-63.
42. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005;7:509-21.
43. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD- 208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-61.
44. Lei X, Wang L, Yang J, Sun LZ. TGF beta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res 2000;2009:15-24.
45. Gold LI. The role of transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10:303-60.
46. Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, et al. Effect of transforming growth factor beta (TGF-b) receptor I kinase inhibitor on prostate cancer bone growth. Bone 2012;50: 695-703.
47. Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, et al. Inhibition of breast cancer metastases by a novel inhibitor of TGFb receptor 1. J Natl Cancer Inst 2013;105:47-58.
48. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
49. Tanaka Y, Terai Y, Kawaguchi H, Fujiwara S, Yoo S, Tsunetoh S, et al. Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther 2013;14: 13-19.